Akademik Veri Yönetim Sistemi
Kastamonu Medical Journal, cilt.3, sa.1, ss.37-40, 2023 (Hakemli Dergi)
Aims: In this study we aimed to share our treatment approach in patients with intermediate -high risk pulmonary embolism
(PE).
Methods: This is a single center retrospective observational study. Patients diagnosed with PE at Akdeniz University Hospital
between January 1, 2015, and January 1, 2021, were retrospectively analyzed. Patients whose diagnosis of PE was confirmed
by computed tomography angiography (CTA) or perfusion/ventilation scintigraphy were considered to have PE. Patients with
intermediate-high risk were included in the study. Patients with a diagnosis of low-risk, low-intermediate risk, high-risk PE,
patients younger than 18 years of age, and pregnant were excluded from the study.
Results: A total of 150 patients, 64 (42.7%) male and 86 (57.3%) female, with a mean age of 62.2±16.2 years, who met the criteria
of these patients were included. 22.7% (34) of the patients received thrombolytic therapy. While 67.7% (23) of the patients who
received thrombolytic therapy received half-dose (50mg rt-PA) thrombolytic therapy, 32.3% (11) received full-dose (100 mg
rt-PA) thrombolytic therapy. Major hemorrhage (3 intracranial hemorrhages, 1 femoral hemorrhage) was detected in 11.7%
(4) of the patients who received thrombolytic therapy.
Conclusion: No significant effect of thrombolytic therapy or full or half dose on mortality was found in the intermediate -high
risk group